1. Home
  2. IKNA vs MCHX Comparison

IKNA vs MCHX Comparison

Compare IKNA & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • MCHX
  • Stock Information
  • Founded
  • IKNA 2016
  • MCHX 2003
  • Country
  • IKNA United States
  • MCHX United States
  • Employees
  • IKNA N/A
  • MCHX N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • IKNA Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • IKNA Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • IKNA 74.8M
  • MCHX 79.9M
  • IPO Year
  • IKNA 2021
  • MCHX 2004
  • Fundamental
  • Price
  • IKNA $1.57
  • MCHX $1.95
  • Analyst Decision
  • IKNA Buy
  • MCHX
  • Analyst Count
  • IKNA 2
  • MCHX 0
  • Target Price
  • IKNA $3.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • IKNA 399.7K
  • MCHX 104.2K
  • Earning Date
  • IKNA 11-07-2024
  • MCHX 10-31-2024
  • Dividend Yield
  • IKNA N/A
  • MCHX N/A
  • EPS Growth
  • IKNA N/A
  • MCHX N/A
  • EPS
  • IKNA N/A
  • MCHX N/A
  • Revenue
  • IKNA $659,000.00
  • MCHX $48,594,000.00
  • Revenue This Year
  • IKNA N/A
  • MCHX N/A
  • Revenue Next Year
  • IKNA N/A
  • MCHX $4.63
  • P/E Ratio
  • IKNA N/A
  • MCHX N/A
  • Revenue Growth
  • IKNA N/A
  • MCHX N/A
  • 52 Week Low
  • IKNA $1.22
  • MCHX $1.11
  • 52 Week High
  • IKNA $2.17
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 42.72
  • MCHX 50.13
  • Support Level
  • IKNA $1.62
  • MCHX $1.98
  • Resistance Level
  • IKNA $1.94
  • MCHX $2.06
  • Average True Range (ATR)
  • IKNA 0.10
  • MCHX 0.16
  • MACD
  • IKNA -0.01
  • MCHX -0.02
  • Stochastic Oscillator
  • IKNA 16.85
  • MCHX 18.18

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: